Predict your next investment

Avion Pharmaceuticals company logo
HEALTHCARE | Pharmaceuticals / Drugs
avionrx.com

See what CB Insights has to offer

Business Relationships

5

Avion Pharmaceuticals Partners & Customers

5 Partners and customers

Avion Pharmaceuticals has 5 strategic partners and customers. Avion Pharmaceuticals recently partnered with ImmuPharma on November 11, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

11/25/2020

Licensor

ImmuPharma

United Kingdom

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3 lupus clinical trial

Dr Tim Franklin , Chief Operating Officer of ImmuPharma PLC joins Proactive London 's Katie Pilbeam to discuss ImmuPharma PLC 's announcement that The US Food & Drug Administration has confirmed 4th December 2020 will be the date for the Type ` A ' Meeting Request , with Avion Pharmaceuticals , ImmuPharma PLC 's licensing partner for Lupuzor ™ .

2

11/12/2020

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/28/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/16/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/14/2014

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

11/25/2020

11/12/2020

11/28/2019

7/16/2019

8/14/2014

Type

Licensor

Licensee

Licensor

Licensor

Licensor

Business Partner

ImmuPharma

Country

United Kingdom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3 lupus clinical trial

Dr Tim Franklin , Chief Operating Officer of ImmuPharma PLC joins Proactive London 's Katie Pilbeam to discuss ImmuPharma PLC 's announcement that The US Food & Drug Administration has confirmed 4th December 2020 will be the date for the Type ` A ' Meeting Request , with Avion Pharmaceuticals , ImmuPharma PLC 's licensing partner for Lupuzor ™ .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.